# A Study to Assess the Effect of Maintenance Treatment With Rituximab Versus No Treatment in Participants With Progressive B-Cell Chronic Lymphocytic Leukemia (CLL)

> **NCT00718549** · PHASE3 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 128 (actual)

## Conditions studied

- Lymphocytic Leukemia, Chronic

## Interventions

- **DRUG:** Cladribine
- **DRUG:** Cyclophosphamide
- **DRUG:** Rituximab

## Key facts

- **NCT ID:** NCT00718549
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-07-21
- **Primary completion:** 2015-09-14
- **Final completion:** 2015-09-14
- **Target enrollment:** 128 (ACTUAL)
- **Last updated:** 2018-08-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00718549

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00718549, "A Study to Assess the Effect of Maintenance Treatment With Rituximab Versus No Treatment in Participants With Progressive B-Cell Chronic Lymphocytic Leukemia (CLL)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00718549. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*